Adamas Pharmaceuticals Inc. buy klostergang
Summary
This prediction ended on 04.09.17 with a price of €19.20. With a performance of 48.99% the BUY prediction by klostergang was a big success. klostergang has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Adamas Pharmaceuticals Inc. | - | - | - | - |
iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
Comments by klostergang for this prediction
In the thread Adamas Pharmaceuticals Inc. diskutieren
Adamas's ADS-5102 could become the first FDA approved drug for Parkinson's disease
klostergang stimmt am 20.08.2017 der fundamentalen Bewertung mit dem Ergebnis unterbewertet zu.
FDA has given a vote of confidence to ADS-5102 by approving NDA application and granting upcoming PDUFDA date of August 24.
A 3-star ranked Cowen analyst reiterated Buy rating on the stock earlier this week with $45 price target. The analyst expressed confidence in ADS-5102's approval and appreciated the management's preparations for commercialization. Armistice Capital, a well-known institutional investor (with $500 million in AUM) bought 1.14 million shares in June 2017 (5.1% stake). Parkinson's disease is also a hot therapeutic area for M&A as shown by recent $1.1B Neuroderm acquisition, $624 million acquisition of Cynapsus Therapeutics, and $363 million acquisition of Biotie.
The company is well-funded with $145 million in cash reserves at the end of Q2'17. It had $33.7 million in long-term debt. At operating cash burn of $26.6B in H1'17, there is no immediate need to raise capital in next 12 months.
Stopped prediction by klostergang for Adamas Pharmaceuticals Inc.
Adamas Pharmaceuticals Inc.
15.03.20
04.11.21
17.06.21
Adamas Pharmaceuticals Inc.
01.10.19
19.12.19
19.12.19
Adamas Pharmaceuticals Inc.
08.09.17
08.08.19
08.08.19